Cyclerion Therapeutics, Inc.

Symbol: CYCN

NASDAQ

3.0496

USD

Market price today

  • -1.4832

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 8.26M

    MRK Cap

  • 0.00%

    DIV Yield

Cyclerion Therapeutics, Inc. (CYCN) Financial Statements

On the chart you can see the default numbers in dynamics for Cyclerion Therapeutics, Inc. (CYCN). Companys revenue shows the average of 1.489 M which is -0.279 % gowth. The average gross profit for the whole period is 1.412 M which is -0.310 %. The average gross profit ratio is 0.520 %. The net income growth for the company last year performance is -0.520 % which equals 0.155 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Cyclerion Therapeutics, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.260. In the realm of current assets, CYCN clocks in at 8.024 in the reporting currency. A significant portion of these assets, precisely 7.571, is held in cash and short-term investments. This segment shows a change of -0.434% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 5.35, if any, in the reporting currency. This indicates a difference of 0.000% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 0 in the reporting currency. This figure signifies a year_over_year change of 0.000%. Shareholder value, as depicted by the total shareholder equity, is valued at 11.288 in the reporting currency. The year over year change in this aspect is 0.080%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 0, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

balance-sheet.row.cash-and-short-term-investments

29.497.613.454
54.4
94.9
0
0

balance-sheet.row.short-term-investments

0000
0
0
0
0

balance-sheet.row.net-receivables

0.100.10.1
0.1
1.5
0
0

balance-sheet.row.inventory

0.5700.80.9
0.8
2
0
0

balance-sheet.row.other-current-assets

0.9700.50.5
3.2
2.9
0
0

balance-sheet.row.total-current-assets

33.34814.855.5
58.5
101.2
0.9
1.3

balance-sheet.row.property-plant-equipment-net

2.301.21.5
50.3
79.8
6.5
4.1

balance-sheet.row.goodwill

0000
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0

balance-sheet.row.long-term-investments

10.75.300
3.8
5
0
0

balance-sheet.row.tax-assets

0000
0
0
0
0

balance-sheet.row.other-non-current-assets

3.81022.4
2.8
0.5
0
0.1

balance-sheet.row.total-non-current-assets

16.85.33.33.9
56.9
85.3
6.5
4.2

balance-sheet.row.other-assets

0000
0
0
0
0

balance-sheet.row.total-assets

50.1413.418.159.3
115.4
186.5
7.4
5.5

balance-sheet.row.account-payables

7.81.231.8
1.4
3.3
2.8
1.8

balance-sheet.row.short-term-debt

0000
6.8
3.4
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0

balance-sheet.row.long-term-debt-total

0000
38.9
70.5
0
0

Deferred Revenue Non Current

0000
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-

balance-sheet.row.other-current-liab

9.10.94.79.3
0.2
0.4
15.1
12.2

balance-sheet.row.total-non-current-liabilities

3.92030
38.9
70.5
0
0

balance-sheet.row.other-liabilities

-3.920-30
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
42.2
73.9
0
0

balance-sheet.row.total-liab

16.912.17.611.1
55.9
88.7
17.8
14

balance-sheet.row.preferred-stock

0000
0
0
0
0

balance-sheet.row.common-stock

0000
0
0
0
0

balance-sheet.row.retained-earnings

-1063.54-264.4-259.2-215.1
-163.4
-85.6
0
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

-0.07000
0
0
-15.5
-15.9

balance-sheet.row.other-total-stockholders-equity

1096.84275.7269.6263.3
222.9
183.4
5
7.3

balance-sheet.row.total-stockholders-equity

33.2411.310.548.2
59.5
97.7
-10.4
-8.6

balance-sheet.row.total-liabilities-and-stockholders-equity

50.1413.418.159.3
115.4
186.5
7.4
5.5

balance-sheet.row.minority-interest

0000
0
0
0
0

balance-sheet.row.total-equity

33.2411.310.548.2
59.5
97.7
-10.4
-

balance-sheet.row.total-liabilities-and-total-equity

50.14---
-
-
-
-

Total Investments

10.75.300
3.8
5
0
0

balance-sheet.row.total-debt

0000
45.7
73.9
0
0

balance-sheet.row.net-debt

-29.49-7.6-13.4-54
-8.7
-21
0
0

Cash Flow Statement

The financial landscape of Cyclerion Therapeutics, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.477. The company recently extended its share capital by issuing 5.02, marking a difference of 0.000 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to 10402000.000 in the reporting currency. This is a shift of 0.000 from the previous year. In the same period, the company recorded 0, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 5.02, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

cash-flows.row.net-income

-5.26-5.3-44.1-51.6
-77.8
-123
-115.3
-93.9

cash-flows.row.depreciation-and-amortization

000.10.5
2.3
2.7
1.5
1.7

cash-flows.row.deferred-income-tax

00-5.22.8
-2.7
0
0
0

cash-flows.row.stock-based-compensation

1.071.16.39.6
15
19.6
12.4
9.5

cash-flows.row.change-in-working-capital

-4.6-4.6-2.91.4
-7.6
-2.3
3.8
1.5

cash-flows.row.account-receivables

0.10.100
1.3
-1.5
0
0

cash-flows.row.inventory

0000
-4.4
-3.2
0
0

cash-flows.row.account-payables

-1.77-1.81.10.4
-1.1
-0.3
1
0.4

cash-flows.row.other-working-capital

-2.921.7-41
-3.5
2.6
2.8
1.1

cash-flows.row.other-non-cash-items

-12.45-12.45.20.9
-1.7
0.8
0
0

cash-flows.row.net-cash-provided-by-operating-activities

-21.25000
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0000
-1.5
-6.9
-3.4
-1.4

cash-flows.row.acquisitions-net

10.410.401.5
1.5
0.2
0
0

cash-flows.row.purchases-of-investments

0000
0
0
0
0

cash-flows.row.sales-maturities-of-investments

0000
0
0
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

10.410.401.5
0
-6.7
-3.4
-1.4

cash-flows.row.debt-repayment

0000
-3.5
0
0
0

cash-flows.row.common-stock-issued

5.025030.5
24.3
175
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0

cash-flows.row.other-financing-activites

0500.3
7.3
36.6
100.9
82.6

cash-flows.row.net-cash-used-provided-by-financing-activities

5.025030.8
28.1
211.6
100.9
82.6

cash-flows.row.effect-of-forex-changes-on-cash

0.01000
0
0
0
0

cash-flows.row.net-change-in-cash

-5.81-5.8-40.6-4.3
-44.4
102.6
0
0

cash-flows.row.cash-at-end-of-period

29.497.613.454
58.2
102.6
0
0

cash-flows.row.cash-at-beginning-of-period

35.313.45458.2
102.6
0
0
0

cash-flows.row.operating-cash-flow

-21.25-21.2-40.6-36.5
-72.5
-102.2
-97.5
-81.2

cash-flows.row.capital-expenditure

0000
-1.5
-6.9
-3.4
-1.4

cash-flows.row.free-cash-flow

-21.25-21.2-40.6-36.5
-74
-109.1
-100.9
-82.6

Income Statement Row

Cyclerion Therapeutics, Inc.'s revenue saw a change of -1.000% compared with the previous period. The gross profit of CYCN is reported to be 0. The company's operating expenses are 9.65, showing a change of -78.403% from the last year. The expenses for depreciation and amortization are 0, which is a 0.000% change from the last accounting period. Operating expenses are reported to be 9.65, which shows a -78.403% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.783% year-over-year growth. The operating income is -9.65, which shows a -0.783% change when compared to the previous year. The change in the net income is -0.520%. The net income for the last year was -21.02.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

income-statement-row.row.total-revenue

000.33.3
2.3
4.5
0
0

income-statement-row.row.cost-of-revenue

000.10.5
0
0
0
0

income-statement-row.row.gross-profit

000.22.8
2.3
4.5
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

5.26---
-
-
-
-

income-statement-row.row.selling-general-administrative

10.53---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.other-expenses

00-1.3-0.6
0
0
0
0

income-statement-row.row.operating-expenses

15.799.644.757.6
85.2
129.5
115.3
93.9

income-statement-row.row.cost-and-expenses

15.799.644.757.6
85.2
129.5
115.3
93.9

income-statement-row.row.interest-income

0.270.40.30
0.6
2
0
0

income-statement-row.row.interest-expense

0.0900.30
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-3.05-2.90.33.5
3.5
2
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

00-1.3-0.6
0
0
0
0

income-statement-row.row.total-operating-expenses

-3.05-2.90.33.5
3.5
2
0
0

income-statement-row.row.interest-expense

0.0900.30
0
0
0
0

income-statement-row.row.depreciation-and-amortization

6.6100.11.4
-3.9
2.7
1.5
1.7

income-statement-row.row.ebitda-caps

-12.49---
-
-
-
-

income-statement-row.row.operating-income

-19.09-9.6-44.4-55.2
-81.3
-125
-115.3
-93.9

income-statement-row.row.income-before-tax

-18.74-12.6-44.1-51.6
-77.8
-123
-115.3
-93.9

income-statement-row.row.income-tax-expense

-17.068.4-0.30
-5.1
-2
0
0

income-statement-row.row.net-income

-5.09-21-43.8-51.7
-72.7
-121
-115.3
-93.9

Frequently Asked Question

What is Cyclerion Therapeutics, Inc. (CYCN) total assets?

Cyclerion Therapeutics, Inc. (CYCN) total assets is 13374000.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.000.

What is company free cash flow?

The free cash flow is -8.587.

What is enterprise net profit margin?

The net profit margin is 0.000.

What is firm total revenue?

The total revenue is 0.000.

What is Cyclerion Therapeutics, Inc. (CYCN) net profit (net income)?

The net profit (net income) is -21015000.000.

What is firm total debt?

The total debt is 0.000.

What is operating expences number?

The operating expences are 9647000.000.

What is company cash figure?

Enretprise cash is 7571000.000.